Skip to main content
Top
Published in: Endocrine 1/2014

01-02-2014 | Original Article

Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism

Authors: Kemal Ağbaht, Murat Faik Erdogan, Rifat Emral, Nilgun Baskal, Sevim Güllü

Published in: Endocrine | Issue 1/2014

Login to get access

Abstract

Due to stimulated overall metabolism, a state of nutritional inadequacy often ensues, during thyrotoxicosis. We aimed to investigate circulating levels of some major components of the system that regulates energy stores, glucose, and fat metabolism, during thyrotoxicosis compared to euthyroidism. Fasting serum ghrelin, leptin, adiponectin, insulin, glucagon, glucose, as well as body fat composition were analyzed during thyrotoxicosis in 40 hyperthyroid patients (50.5 ± 15.2 years old, 22 females, 31 with Graves disease, and 9 with toxic nodular goiter). The same measurements were repeated an average 3 months later, when all patients achieved euthyroidism. Compared to euthyroidism, in thyrotoxicosis, patients had lower ghrelin and fat mass; had comparable insulin, HOMA-IR, glucagon, and leptin levels; higher levels of circulating adiponectin. Fasting serum glucose tended to be higher during thyrotoxicosis. The unique correlation of HOMA-IR was with the-glucagon to ghrelin ratio-(r = 0.801, p < 0.001) in hyperthyrodism, and with glucagon itself in euthyroidism (r = −0.844, p < 0.001). Circulating levels of ghrelin are decreased; leptin, insulin, glucagon are unchanged; adiponectin are increased during hyperthyroidism. The fasting HOMA-IR tends to be higher, despite the decreased adiposity in hyperthyroidism. The-glucagon to ghrelin ratio-strongly correlates with fasting HOMA-IR in hyperthyroidism.
Literature
2.
go back to reference M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed M.W. Schwartz, S.C. Woods, D. Porte Jr, R.J. Seeley, D.G. Baskin, Central nervous system control of food intake. Nature 404, 661–671 (2000)PubMed
3.
go back to reference A. Sainsbury, G.J. Cooney, H. Herzog, Hypothalamic regulation of energy homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 16, 623–637 (2002)PubMedCrossRef A. Sainsbury, G.J. Cooney, H. Herzog, Hypothalamic regulation of energy homeostasis. Best Pract. Res. Clin. Endocrinol. Metab. 16, 623–637 (2002)PubMedCrossRef
4.
go back to reference S.M. Poykko, E. Kellokoski, S. Horkko, H. Kauma, Y.A. Kesaniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef S.M. Poykko, E. Kellokoski, S. Horkko, H. Kauma, Y.A. Kesaniemi, O. Ukkola, Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52, 2546–2553 (2003)PubMedCrossRef
5.
go back to reference A. Ikezaki, H. Hosoda, K. Ito, S. Iwama, N. Miura, H. Matsuoka, C. Kondo, M. Kojima, K. Kangawa, S. Sugihara, Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51, 3408–3411 (2002)PubMedCrossRef A. Ikezaki, H. Hosoda, K. Ito, S. Iwama, N. Miura, H. Matsuoka, C. Kondo, M. Kojima, K. Kangawa, S. Sugihara, Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51, 3408–3411 (2002)PubMedCrossRef
6.
go back to reference Y. Li, J. Hai, L. Li, X. Chen, H. Peng, M. Cao, Q. Zhang, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 43(2), 376–386 (2012)PubMedCrossRef Y. Li, J. Hai, L. Li, X. Chen, H. Peng, M. Cao, Q. Zhang, Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. Endocrine 43(2), 376–386 (2012)PubMedCrossRef
7.
go back to reference B.W. Liu, Q. Lu, C.M. Ma, J.R. Liu, D.H. Lou, X.L. Liu, F.Z. Yin, The study of soluble intercellular adhesion molecule-1 and ghrelin in adolescents with family history of type 2 diabetes. Endocrine 42, 599–605 (2012)PubMedCrossRef B.W. Liu, Q. Lu, C.M. Ma, J.R. Liu, D.H. Lou, X.L. Liu, F.Z. Yin, The study of soluble intercellular adhesion molecule-1 and ghrelin in adolescents with family history of type 2 diabetes. Endocrine 42, 599–605 (2012)PubMedCrossRef
8.
go back to reference P.J. Delhanty, A.J. van der Lely, Ghrelin: a new treatment for non-alcoholic fatty liver disease? Endocrine 43(2), 247–248 (2012)PubMedCrossRef P.J. Delhanty, A.J. van der Lely, Ghrelin: a new treatment for non-alcoholic fatty liver disease? Endocrine 43(2), 247–248 (2012)PubMedCrossRef
9.
go back to reference J.C. Chuang, I. Sakata, D. Kohno, M. Perello, S. Osborne-Lawrence, J.J. Repa, J.M. Zigman, Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol. Endocrinol. 25, 1600–1611 (2011)PubMedCrossRef J.C. Chuang, I. Sakata, D. Kohno, M. Perello, S. Osborne-Lawrence, J.J. Repa, J.M. Zigman, Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol. Endocrinol. 25, 1600–1611 (2011)PubMedCrossRef
10.
go back to reference M.A. Arafat, B. Otto, H. Rochlitz, M. Tschop, V. Bahr, M. Mohlig, S. Diederich, J. Spranger, A.F. Pfeiffer, Glucagon inhibits ghrelin secretion in humans. Eur. J. Endocrinol. 153, 397–402 (2005)PubMedCrossRef M.A. Arafat, B. Otto, H. Rochlitz, M. Tschop, V. Bahr, M. Mohlig, S. Diederich, J. Spranger, A.F. Pfeiffer, Glucagon inhibits ghrelin secretion in humans. Eur. J. Endocrinol. 153, 397–402 (2005)PubMedCrossRef
11.
go back to reference A.E. Altinova, F.B. Toruner, M. Akturk, S. Elbeg, I. Yetkin, N. Cakir, M. Arslan, Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm. Res. 65, 295–299 (2006)PubMedCrossRef A.E. Altinova, F.B. Toruner, M. Akturk, S. Elbeg, I. Yetkin, N. Cakir, M. Arslan, Reduced serum acylated ghrelin levels in patients with hyperthyroidism. Horm. Res. 65, 295–299 (2006)PubMedCrossRef
12.
go back to reference O. Gimenez-Palop, G. Gimenez-Perez, D. Mauricio, E. Berlanga, N. Potau, C. Vilardell, J. Arroyo, J.M. Gonzalez-Clemente, A. Caixas, Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur. J. Endocrinol. 153, 73–79 (2005)PubMedCrossRef O. Gimenez-Palop, G. Gimenez-Perez, D. Mauricio, E. Berlanga, N. Potau, C. Vilardell, J. Arroyo, J.M. Gonzalez-Clemente, A. Caixas, Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur. J. Endocrinol. 153, 73–79 (2005)PubMedCrossRef
13.
go back to reference A.L. Riis, T.K. Hansen, N. Moller, J. Weeke, J.O. Jorgensen, Hyperthyroidism is associated with suppressed circulating ghrelin levels. J. Clin. Endocrinol. Metab. 88, 853–857 (2003)PubMedCrossRef A.L. Riis, T.K. Hansen, N. Moller, J. Weeke, J.O. Jorgensen, Hyperthyroidism is associated with suppressed circulating ghrelin levels. J. Clin. Endocrinol. Metab. 88, 853–857 (2003)PubMedCrossRef
14.
go back to reference G. Dimitriadis, E. Hatziagelaki, P. Mitrou, V. Lambadiari, E. Maratou, A.E. Raptis, J.E. Gerich, S.A. Raptis, Effect of hyperthyroidism on clearance and secretion of glucagon in man. Exp. Clin. Endocrinol. Diabetes 119, 214–217 (2011)PubMedCrossRef G. Dimitriadis, E. Hatziagelaki, P. Mitrou, V. Lambadiari, E. Maratou, A.E. Raptis, J.E. Gerich, S.A. Raptis, Effect of hyperthyroidism on clearance and secretion of glucagon in man. Exp. Clin. Endocrinol. Diabetes 119, 214–217 (2011)PubMedCrossRef
15.
go back to reference N. Pontikides, G.E. Krassas, Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 17, 421–431 (2007)PubMedCrossRef N. Pontikides, G.E. Krassas, Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid 17, 421–431 (2007)PubMedCrossRef
16.
go back to reference D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)PubMedCrossRef
17.
go back to reference M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, M.L. Heiman, Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709 (2001)PubMedCrossRef
18.
go back to reference J. Nedvidkova, I. Krykorkova, V. Bartak, H. Papezova, P.W. Gold, S. Alesci, K. Pacak, Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 88, 1678–1682 (2003)PubMedCrossRef J. Nedvidkova, I. Krykorkova, V. Bartak, H. Papezova, P.W. Gold, S. Alesci, K. Pacak, Loss of meal-induced decrease in plasma ghrelin levels in patients with anorexia nervosa. J. Clin. Endocrinol. Metab. 88, 1678–1682 (2003)PubMedCrossRef
19.
go back to reference S. Rojdmark, J. Calissendorff, O. Danielsson, K. Brismar, Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27, 55–61 (2005)PubMedCrossRef S. Rojdmark, J. Calissendorff, O. Danielsson, K. Brismar, Hunger-satiety signals in patients with Graves’ thyrotoxicosis before, during, and after long-term pharmacological treatment. Endocrine 27, 55–61 (2005)PubMedCrossRef
20.
go back to reference J. Kosowicz, A. Baumann-Antczak, M. Ruchala, M. Gryczynska, E. Gurgul, J. Sowinski, Thyroid hormones affect plasma ghrelin and obestatin levels. Horm. Metab. Res. 43, 121–125 (2011)PubMedCrossRef J. Kosowicz, A. Baumann-Antczak, M. Ruchala, M. Gryczynska, E. Gurgul, J. Sowinski, Thyroid hormones affect plasma ghrelin and obestatin levels. Horm. Metab. Res. 43, 121–125 (2011)PubMedCrossRef
21.
go back to reference K. Dezaki, H. Sone, T. Yada, Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118, 239–249 (2008)PubMedCrossRef K. Dezaki, H. Sone, T. Yada, Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol. Ther. 118, 239–249 (2008)PubMedCrossRef
22.
go back to reference G. Dimitriadis, B. Baker, H. Marsh, L. Mandarino, R. Rizza, R. Bergman, M. Haymond, J. Gerich, Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am. J. Physiol. 248, E593–E601 (1985)PubMed G. Dimitriadis, B. Baker, H. Marsh, L. Mandarino, R. Rizza, R. Bergman, M. Haymond, J. Gerich, Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am. J. Physiol. 248, E593–E601 (1985)PubMed
23.
go back to reference P. Mitrou, S.A. Raptis, G. Dimitriadis, Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr. Rev. 31, 663–679 (2010)PubMedCrossRef P. Mitrou, S.A. Raptis, G. Dimitriadis, Insulin action in hyperthyroidism: a focus on muscle and adipose tissue. Endocr. Rev. 31, 663–679 (2010)PubMedCrossRef
24.
go back to reference G. Dimitriadis, P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, E. Koukkou, M. Tzanela, N. Thalassinos, S.A. Raptis, Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J. Clin. Endocrinol. Metab. 91, 1112–1118 (2006)PubMedCrossRef G. Dimitriadis, P. Mitrou, V. Lambadiari, E. Boutati, E. Maratou, E. Koukkou, M. Tzanela, N. Thalassinos, S.A. Raptis, Glucose and lipid fluxes in the adipose tissue after meal ingestion in hyperthyroidism. J. Clin. Endocrinol. Metab. 91, 1112–1118 (2006)PubMedCrossRef
25.
go back to reference U.M. Kabadi, A.B. Eisenstein, Glucose intolerance in hyperthyroidism: role of glucagon. J. Clin. Endocrinol. Metab. 50, 392–396 (1980)PubMedCrossRef U.M. Kabadi, A.B. Eisenstein, Glucose intolerance in hyperthyroidism: role of glucagon. J. Clin. Endocrinol. Metab. 50, 392–396 (1980)PubMedCrossRef
26.
go back to reference U.M. Kabadi, A.B. Eisenstein, Impaired pancreatic alpha-cell response in hyperthyroidism. J. Clin. Endocrinol. Metab. 51, 478–482 (1980)PubMedCrossRef U.M. Kabadi, A.B. Eisenstein, Impaired pancreatic alpha-cell response in hyperthyroidism. J. Clin. Endocrinol. Metab. 51, 478–482 (1980)PubMedCrossRef
27.
go back to reference J.E. Gerich, M. Langlois, C. Noacco, V. Schneider, P.H. Forsham, Adrenergic modulation of pancreatic glucagon secretion in man. J. Clin. Invest. 53, 1441–1446 (1974)PubMedCentralPubMedCrossRef J.E. Gerich, M. Langlois, C. Noacco, V. Schneider, P.H. Forsham, Adrenergic modulation of pancreatic glucagon secretion in man. J. Clin. Invest. 53, 1441–1446 (1974)PubMedCentralPubMedCrossRef
28.
go back to reference P. Iglesias, J.J. Diez, Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 40, 61–70 (2007)PubMedCrossRef P. Iglesias, J.J. Diez, Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine 40, 61–70 (2007)PubMedCrossRef
29.
go back to reference H. Wahrenberg, A. Wennlund, J. Hoffstedt, Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur. J. Endocrinol. 146, 607–611 (2002)PubMedCrossRef H. Wahrenberg, A. Wennlund, J. Hoffstedt, Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves’ hyperthyroidism. Eur. J. Endocrinol. 146, 607–611 (2002)PubMedCrossRef
30.
go back to reference R. Seven, Thyroid status and leptin in Basedow-Graves and multinodular goiter patients. J. Toxicol. Environ. Health A. 63, 575–581 (2001)PubMedCrossRef R. Seven, Thyroid status and leptin in Basedow-Graves and multinodular goiter patients. J. Toxicol. Environ. Health A. 63, 575–581 (2001)PubMedCrossRef
31.
go back to reference S. Corbetta, P. Englaro, S. Giambona, L. Persani, W.F. Blum, P. Beck-Peccoz, Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur. J. Endocrinol. 137, 659–663 (1997)PubMedCrossRef S. Corbetta, P. Englaro, S. Giambona, L. Persani, W.F. Blum, P. Beck-Peccoz, Lack of effects of circulating thyroid hormone levels on serum leptin concentrations. Eur. J. Endocrinol. 137, 659–663 (1997)PubMedCrossRef
32.
go back to reference S. Yaturu, S. Prado, S.R. Grimes, Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J. Cell. Biochem. 93, 491–496 (2004)PubMedCrossRef S. Yaturu, S. Prado, S.R. Grimes, Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction. J. Cell. Biochem. 93, 491–496 (2004)PubMedCrossRef
34.
go back to reference R. Coppari, M. Ichinose, C.E. Lee, A.E. Pullen, C.D. Kenny, R.A. McGovern, V. Tang, S.M. Liu, T. Ludwig, S.C. Chua Jr, B.B. Lowell, J.K. Elmquist, The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 1, 63–72 (2005)PubMedCrossRef R. Coppari, M. Ichinose, C.E. Lee, A.E. Pullen, C.D. Kenny, R.A. McGovern, V. Tang, S.M. Liu, T. Ludwig, S.C. Chua Jr, B.B. Lowell, J.K. Elmquist, The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 1, 63–72 (2005)PubMedCrossRef
35.
go back to reference N. Kubota, W. Yano, T. Kubota, T. Yamauchi, S. Itoh, H. Kumagai, H. Kozono, I. Takamoto, S. Okamoto, T. Shiuchi, R. Suzuki, H. Satoh, A. Tsuchida, M. Moroi, K. Sugi, T. Noda, H. Ebinuma, Y. Ueta, T. Kondo, E. Araki, O. Ezaki, R. Nagai, K. Tobe, Y. Terauchi, K. Ueki, Y. Minokoshi, T. Kadowaki, Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6, 55–68 (2007)PubMedCrossRef N. Kubota, W. Yano, T. Kubota, T. Yamauchi, S. Itoh, H. Kumagai, H. Kozono, I. Takamoto, S. Okamoto, T. Shiuchi, R. Suzuki, H. Satoh, A. Tsuchida, M. Moroi, K. Sugi, T. Noda, H. Ebinuma, Y. Ueta, T. Kondo, E. Araki, O. Ezaki, R. Nagai, K. Tobe, Y. Terauchi, K. Ueki, Y. Minokoshi, T. Kadowaki, Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6, 55–68 (2007)PubMedCrossRef
36.
go back to reference T. Saito, T. Kawano, A. Ikoma, K. Namai, H. Tamemoto, M. Kawakami, S.E. Ishikawa, Elevation of serum adiponectin levels in Basedow disease. Metabolism 54, 1461–1466 (2005)PubMedCrossRef T. Saito, T. Kawano, A. Ikoma, K. Namai, H. Tamemoto, M. Kawakami, S.E. Ishikawa, Elevation of serum adiponectin levels in Basedow disease. Metabolism 54, 1461–1466 (2005)PubMedCrossRef
Metadata
Title
Circulating glucagon to ghrelin ratio as a determinant of insulin resistance in hyperthyroidism
Authors
Kemal Ağbaht
Murat Faik Erdogan
Rifat Emral
Nilgun Baskal
Sevim Güllü
Publication date
01-02-2014
Publisher
Springer US
Published in
Endocrine / Issue 1/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-9951-9

Other articles of this Issue 1/2014

Endocrine 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.